Evolution of Pharmaceutical Expenditure and Cost Avoidance in Cancer Clinical Trials: A 10-Year Retrospective Study of Adult Solid Tumor Patients (Highlights longitudinal “evolution” in drug patterns alongside DCA.)

This retrospective review from a single institution aimed to outline the clinical profile of adult individuals with solid malignancies who entered oncology trials across a decade (2010–2019) and to quantify drug cost avoidance (DCA) attributable to sponsor-funded treatments. Sponsor-supported pharmaceutical costs were estimated using the annual market price of each antineoplastic product that Vall d’Hebron University Hospital (HUVH) would otherwise have paid. Across the study window, 2930 trials were run, enrolling 10, 488 subjects. The number of studies rose from 140 in 2010 to 459 in 2019 (a 228% rise). Early-phase, high-complexity designs—such as phase I and basket studies—represented 34.3% of all trials. Marked shifts in research trends were observed: in 2010, targeted agents represented 79.4% of drug spending and cytotoxics 20.6%, whereas by 2019, immunotherapies made up 68.4%, targeted agents 24.4%, and cytotoxic drugs only 7.1%. Altogether, 421 distinct anticancer medicines were employed; diversity expanded from 47 agents used in 2010 (with 7 of them responsible for 92.8% of expenses) to 317 agents in 2019 (with 33 accounting for 90.6% of spending). Total antineoplastic expenditure for patients treated outside trial settings was EUR 120, 396, 096. The value of investigational medications supplied by sponsors reached EUR 107, 306, 084, generating a potential DCA of EUR 92, 662, 609. Overall, clinical trials not only advance medical innovation and patient care but also offer substantial opportunities to mitigate oncology-related costs.